Researchers at Moffitt Cancer Center have completed a phase II clinical trial to determine the safety and efficacy of dasatinib for patients with higher-risk myelodysplastic syndromes , chronic myelomonocytic leukemia, or acute myeloid leukemia resulting from MDS and have failed treatment with azanucleosides.
http://www.medilexicon.com/medicalnews.php?newsid=258088
http://www.medilexicon.com/medicalnews.php?newsid=258088
No comments:
Post a Comment